In vivo demonstration of an antithrombin effect of abciximab

John A. Ambrose, Marian Hawkey, Juan J. Badimon, John Coppola, Jean Pierre Geagea, K. Peter Rentrop, Alvaro Domiguez, Srinivas Duvvuri, Thomas Elmquist, Jose Arias, Ramy Doss, George Dangas

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Abciximab prolonged the activated clotting time (ACT) in a post hoc analysis from the Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications trial and an in vitro study has suggested an antithrombin effect of platelet glycoprotein IIb/IIIa inhibition. The purpose of this study was to evaluate the in vivo effects of abciximab on ACT and thrombin generation. In 46 patients undergoing coronary intervention, 24 received heparin and abciximab (group I), whereas 22 received heparin alone (group II). All received the same dose (70 U/kg) of heparin. Heparin was given after a baseline ACT, and in group I, abciximab was administered after the 5-minute ACT. Serial ACTs were recorded at baseline, 5, 10, 20, and every 30 minutes thereafter and at the procedure's end. No intervention including balloon angioplasty was performed until after the 20-minute ACT. The prothrombin fragment F1.2 (Nm/L) was measured at baseline, 20 minutes, and at the end of the procedure. Before (baseline) heparin and at 5 minutes, ACTs were similar. Abciximab prolonged ACT by a mean of 34 to 64 seconds starting with the 10-minute ACT and extending to the 50-minute ACT (all p <0.01 vs heparin alone). There was a progressive decrease in the F1.2 with abciximab, and baseline minus end F1.2 was 0.12 ± 0.02 in group I versus 0.05 ± 0.04 in group II, p <0.05. These data indicate a significant in vivo effect of abciximab plus heparin in increasing ACT and decreasing F1.2, results that are consistent with an effect on reducing thrombin generation.

Original languageEnglish
Pages (from-to)150-152
Number of pages3
JournalAmerican Journal of Cardiology
Issue number2
StatePublished - Jul 2000
Externally publishedYes


Dive into the research topics of 'In vivo demonstration of an antithrombin effect of abciximab'. Together they form a unique fingerprint.

Cite this